Search research articles
Contact Us
Filters
Showing results (11-20 of 39) with videos related to
Page
of 4
Sort By:
Endocrine, Metabolic & Immune Disorders Drug Targets
|
March 10, 2007
Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006
C Kleinschnitz, S G Meuth, B C Kieseier, et al.
Der Nervenarzt
|
June 7, 2007
[Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis]
C Kleinschnitz, S G Meuth, B C Kieseier, et al.
Der Nervenarzt
|
November 18, 2008
[Multiple sclerosis -- a channelopathy? Targeting ion channels and transporters in inflammatory neurodegeneration]
S G Meuth, N Melzer, C Kleinschnitz, et al.
Der Nervenarzt
|
June 8, 2011
[Pregabalin and gabapentin in multiple sclerosis: clinical experiences and therapeutic implications]
S Bittner, K Höhn, K Göbel, et al.
Journal of Neurology
|
April 11, 2022
The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis
A G Willison, T Ruck, G Lenz, et al.
Journal of Neurology
|
May 24, 2022
Correction to: The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis
A G Willison, T Ruck, G Lenz, et al.
Hamostaseologie
|
May 20, 2015
Platelets and vascular inflammation of the brain
M Mezger, K Göbel, P Kraft, et al.
Der Nervenarzt
|
October 29, 2017
[New aspects of symptomatic MS treatment: Part 6 - cognitive dysfunction and rehabilitation]
T Henze, W Feneberg, P Flachenecker, et al.
Frontiers in Immunology
|
September 2, 2024
High socioeconomic impact on prescription behavior despite unrestricted access to disease-modifying therapies in people with multiple sclerosis
S Samadzadeh, J Havla, K Lepka, et al.
Der Nervenarzt
|
October 29, 2017
[New aspects of symptomatic MS treatment: Part 5 - fatigue]
T Henze, W Feneberg, P Flachenecker, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 39) with videos related to
Sort By:
Page
of 4
Endocrine, Metabolic & Immune Disorders Drug Targets
|
March 10, 2007
Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006
C Kleinschnitz, S G Meuth, B C Kieseier, et al.
Der Nervenarzt
|
June 7, 2007
[Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis]
C Kleinschnitz, S G Meuth, B C Kieseier, et al.
Der Nervenarzt
|
November 18, 2008
[Multiple sclerosis -- a channelopathy? Targeting ion channels and transporters in inflammatory neurodegeneration]
S G Meuth, N Melzer, C Kleinschnitz, et al.
Der Nervenarzt
|
June 8, 2011
[Pregabalin and gabapentin in multiple sclerosis: clinical experiences and therapeutic implications]
S Bittner, K Höhn, K Göbel, et al.
Journal of Neurology
|
April 11, 2022
The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis
A G Willison, T Ruck, G Lenz, et al.
Journal of Neurology
|
May 24, 2022
Correction to: The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis
A G Willison, T Ruck, G Lenz, et al.
Hamostaseologie
|
May 20, 2015
Platelets and vascular inflammation of the brain
M Mezger, K Göbel, P Kraft, et al.
Der Nervenarzt
|
October 29, 2017
[New aspects of symptomatic MS treatment: Part 6 - cognitive dysfunction and rehabilitation]
T Henze, W Feneberg, P Flachenecker, et al.
Frontiers in Immunology
|
September 2, 2024
High socioeconomic impact on prescription behavior despite unrestricted access to disease-modifying therapies in people with multiple sclerosis
S Samadzadeh, J Havla, K Lepka, et al.
Der Nervenarzt
|
October 29, 2017
[New aspects of symptomatic MS treatment: Part 5 - fatigue]
T Henze, W Feneberg, P Flachenecker, et al.
Page
of 4